[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633305":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":12,"id":58,"slug":12,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":12,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":79,"whyStopped":12,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Beijing Tongren Hospital","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-antagonistic group","NO_INTERVENTION","No intervention",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Count-2 antagonist group","EXPERIMENTAL","When relaxation monitoring is count 2, administer neostigmine.",[18],"Drug: Neostigmine",{"label":20,"type":15,"description":21,"interventionNames":22},"Train of four stimulation ratio (TOFr) 0.4 antagonist group","When TOFr is 0.4, administer neostigmine.",[18],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":12},"DRUG","Neostigmine","Administer neostigmine at a dose of 0.04 mg\u002Fkg (combined with 0.02 mg\u002Fkg atropine)",[14,20],[30],{"name":31,"affiliation":5,"role":32},"Guyan Wang","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":12,"email":38},"Haiyao Wu","CONTACT","0086 18171485811","haiyaowu0105@163.com",[40],{"facility":41,"status":12,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Beijing tongren Hospital, Capital Medical University","Beijing","Beijing Municipality","100000","China",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":55,"phoneExt":12,"email":38},"Haiyaao Wu","008618171485811",{"type":57,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100633305",false,"NCT07524959","Antagonism of Neostigmine in Continuous Infusion of Mivacurium","Antagonism of Neostigmine in Continuous Infusion of Mivacurium: a Randomised Controlled Trial","Inclusion Criteria:\n\n* 18 - 65 years old;\n* American Society of Anesthesiologists (ASA) physical stastus classification system: I-II;\n* Body mass index (BMI) 18.5 - 30 kg\u002Fm2\n* Patients with normal cholinesterase levels before the operation\n\nExclusion Criteria:\n\n* Refusal to participate in the study;\n* ASA classification of grade III or above;\n* Severe organ dysfunction, difficult airway or neurological muscle disorders;\n* Taking drugs that affect neuromuscular monitoring or neuromuscular conduction function;\n* Allergic to the test drug or having other contraindications;\n* Pregnant and lactating women","ALL","18 Years","65 Years",{"count":68,"type":69},120,"ESTIMATED","INTERVENTIONAL",[72],"NA","In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anesthesia was investigated, and the appropriate time point of antagonism was explored.",[75],"Neuromuscular Blocking Agents",[77,78,26,75],"Neuromuscular Monitoring","Mivacurium","NOT_YET_RECRUITING","2026-04-06",{"date":82,"type":83},"2026-04-13","ACTUAL",{"date":85,"type":69},"2026-05-01",{"date":87,"type":69},"2026-07-29",{"name":5,"class":6},1]